Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas
Open accessAbstract
Adrenocortical carcinoma (ACC) is a rare, highly malignant tumor. The aim of the present study is to evaluate the prognostic relevance of a proliferation marker Ki67/MIB1 by immunohistochemistry in 17 cases who underwent resections of the primary tumors and diagnosed to have ACC at Tohoku University Hospital based on the criteria of Weiss during the period from 1976 to 2005. The follow-up periods ranged from 221 days to 10659 days (about 29 years) with the median of 1895 days. The median age at diagnosis was 46 years old, and the mean size of the primary tumors was 7.1 cm with the minimal of 3.5 cm. Ki67/MIB1 labeling index (Ki67/MIB1LI) ranged from 1% to 26%. Kaplan-Meier analysis revealed that patients with Ki67/MIB1LI of 7% or more were associated with significantly shortened disease-free survival (P = 0.0037). The evaluation with Weiss criteria revealed that the median score of Weiss criteria was five, and 13 patients (76.5%) presented positive findings in the criteria of mitotic rate. The survival analysis with Weiss score showed that patients with the scores of 6 or more had both significantly shortened disease-free survival (P = 0.0001) and overall survival (P = 0.0063). The present study has suggested that Ki67/MIB1LI, as well as Weiss score, is a useful predictor for tumor recurrence after resection of the primary tumors in patients with ACC.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cutoff at which a Ki67 labeling index confirms the diagnosis of ACC and predicts aggressive disease is debated and ranges from >2.5% to >7%.
“The cutoff at which a Ki67 labeling index confirms the diagnosis of ACC and predicts aggressive disease is debated and ranges from >2.5% to >7% (113,115-117).”
From Adrenal incidentaloma (2020) · cites this paper as [116]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors
Weiss, L. M. (1984) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198403000-00001 · Cited by 920 · cited 2× · see citing works
“The diagnosis of ACC has been made according to the criteria of Weiss [6, 7], which is a well-validated and established scoring system for a histopathological diagnosis of ACC [1, 8].”
MethodPathologic features of prognostic significance in adrenocortical carcinoma
Weiss, L. M., Medeiros, L. J., & Vickery, A. L. (1989) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198903000-00004 · Cited by 818 · cited 2× · see citing works
“The diagnosis of ACC has been made according to the criteria of Weiss [6, 7], which is a well-validated and established scoring system for a histopathological diagnosis of ACC [1, 8].”
MethodAdrenocortical Carcinoma: Clinical Update
Allolio, B., & Fassnacht, M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2639 · Cited by 775 · see citing works
Ki67 protein: the immaculate deception?
Brown, D. C., & Gatter, K. C. (2002) · Histopathology · doi:10.1046/j.1365-2559.2002.01343.x · Cited by 511 · see citing works
Management of patients with adrenal cancer: recommendations of an international consensus conference
Schteingart, D. E., Doherty, G. M., Gauger, P. G., Giordano, T. J., Hammer, G. D., Korobkin, M., & Worden, F. P. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.01029 · Cited by 421 · see citing works
Dackiw, A. P. B., Lee, J. E., Gagel, R. F., & Evans, D. B. (2001) · World Journal of Surgery · doi:10.1007/s00268-001-0030-7 · Cited by 390 · see citing works
Incidentally discovered adrenal tumors: an institutional perspective.
Mf, H., Cs, G., van Heerden, J. A., Sheedy, P. F., & Dm, I. (1991) · PubMed · Cited by 360 · see citing works
Adrenocortical Carcinoma: Clinical, Morphologic, and Molecular Characterization
Stojadinovic, A., Ghossein, R. A., Hoos, A., Nissan, A., Marshall, D., Dudas, M. E., Cordon‐Cardo, C., Jaques, D. P., & Brennan, M. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.4.941 · Cited by 312 · see citing works
Management of adrenocortical carcinoma
Allolio, B., Hahner, S., Weismann, D., & Fassnacht, M. (2004) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01881.x · Cited by 214 · see citing works
Immunohistochemical assessment of proliferative activity in adrenocortical neoplasms.
Goldblum, J. R., Shannon, R., Kaldjian, E. P., Thiny, M. T., Davenport, R. D., Thompson, N. W., & Lloyd, R. V. (1993) · PubMed · Cited by 116 · see citing works
Schmitt, A., Saremaslani, P., Schmid, S., Rousson, V, Montani, M., Schmid, D. M., Heitz, P. U., Komminoth, P., & Perren, A. (2006) · Histopathology · doi:10.1111/j.1365-2559.2006.02505.x · Cited by 94 · see citing works
Endl, E., & Gerdes, J. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200003)182:3 · Cited by 89 · see citing works
Adrenocortical Neoplasms: Role of Prognostic Markers MIB-1, P53, and RB
Vargas, M. P., Vargas, H. I., Kleiner, D. E., & Merino, M. J. (1997) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199705000-00008 · Cited by 89 · see citing works
Discerning malignancy in adrenocortical tumors: are molecular markers useful?
Wachenfeld, C., Beuschlein, F., Zwermann, O., Mora, P., Faßnacht, M., Allolio, B., & Reincke, M. (2001) · European Journal of Endocrinology · doi:10.1530/eje.0.1450335 · Cited by 84 · see citing works
Cell proliferation and apoptosis in normal and pathologic human adrenal.
Sasano, H., Imatani, A., Shizawa, S., Suzuki, T., & Nagura, H. (1995) · PubMed · Cited by 83 · see citing works
Self-citationIino, K., Sasano, H., Yabuki, N., Oki, Y., Kikuchi, A., Yoshimi, T., & Nagura, H. (1997) · PubMed · Cited by 62 · see citing works
Self-citationExpression of cell cycle inhibitor p27 and Ki-67 in human adrenocortical neoplasms.
Nakazumi, H., Sasano, H., Iino, K., Ohashi, Y., & Orikasa, S. (1998) · PubMed · Cited by 56 · see citing works
Self-citationProliferation in adrenocortical tumors: Correlation with clinical outcome and p53 status
McNicol, A. M., Struthers, A. J., Nolan, C. E., Hermans, J., & Haak, H. R. (1997) · Endocrine Pathology · doi:10.1007/bf02739705 · Cited by 51 · see citing works
Discerning Malignancy in Resected Adrenocortical Neoplasms
Sasano, H., Suzuki, T., & Moriya, T. (2001) · Endocrine Pathology · doi:10.1385/ep:12:4:397 · Cited by 27 · see citing works
Self-citationWajchenberg (2000) · doi:10.1002/(sici)1097-0142(20000215)88:4
Flagged first, then by citations
Research works printed but not linked: 2
- Allolio B, Fassnacht M (2006) Clinical review: adreno- cortical carcinoma: clinical update. J Clin Endocrinol Metab 91: 2027-2037.
- Norton JA (2005) Adrenal tumors. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology. 7th ed. Lippincott Williams & Wilkins, Philadelphia: 1528-1539.
Cited by
Sorted by citations
Else, T., Kim, A. C., Sabolch, A., Raymond, V. M., Kandathil, A., Caoili, E. M., Jolly, S., Miller, B. S., Giordano, T. J., & Hammer, G. D. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1029 · Cited by 892 · see citing works
Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling
Giordano, T. J., Kuick, R., Else, T., Gauger, P. G., Vinco, M., Bauersfeld, J., Sanders, D., Thomas, D. G., Doherty, G., & Hammer, G. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1067 · Cited by 401 · see citing works
Adrenocortical carcinoma: a clinician’s update
Fassnacht, M., Libé, R., Kroiss, M., & Allolio, B. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.235 · Cited by 396 · see citing works
Clinical management of adrenocortical carcinoma
Fassnacht, M., & Allolio, B. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.10.008 · Cited by 349 · see citing works
Sherlock, M., Scarsbrook, A., Abbas, A., Fraser, S., Limumpornpetch, P., Dineen, R., & Stewart, P. M. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa008 · Cited by 347 · see citing works
Gaujoux, S., Grabar, S., Fassnacht, M., Ragazzon, B., Launay, P., Libé, R., Chokri, I., Audebourg, A., Royer, B., Sbiera, S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2006 · Cited by 146 · see citing works
Habra, M. A., Ejaz, S., Feng, L., Das, P., Deniz, F., Grubbs, E. G., Phan, A., Waguespack, S. G., Ayala-Ramirez, M., Jimenez, C., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2367 · Cited by 101 · see citing works
Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade
Miller, B. S., Gauger, P. G., Hammer, G. D., Giordano, T. J., & Doherty, G. M. (2010) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-010-0698-y · Cited by 84 · see citing works
Challenges in surgical pathology of adrenocortical tumours
Erickson, L. A. (2018) · Histopathology · doi:10.1111/his.13255 · Cited by 70 · see citing works
Nakamura (2015) · doi:10.1016/j.ecl.2015.02.007 · Cited by 55 · see citing works
Radiomic mapping model for prediction of Ki-67 expression in adrenocortical carcinoma
Ahmed, A. A., Elmohr, M. M., Fuentes, D., Habra, M. A., Fisher, S. B., Perrier, N. D., Zhang, M., & Elsayes, K. M. (2020) · Clinical Radiology · doi:10.1016/j.crad.2020.01.012 · Cited by 41 · see citing works
Papotti, M., Duregon, E., Volante, M., & McNicol, A. M. (2014) · Endocrine Pathology · doi:10.1007/s12022-013-9291-6 · Cited by 33 · see citing works
- Authors
- MORIMOTO, R., SATOH, F., MURAKAMI, O., SUZUKI, T., ABE, T., TANEMOTO, M., ABE, M., URUNO, A., ISHIDOYA, S., ARAI, Y., TAKAHASHI, K., SASANO, H., & ITO, S.
- Affiliations
- Tohoku University (JP)
- ORCID
- Venue
- Endocrine Journal
- Publisher
- Japan Endocrine Society
- Published
- 2008
- Volume
- 55
- Issue
- 1
- Pages
- 49-55
- ISSN
- 0918-8959 (ISSN-L)
- 1348-4540
- OpenAlex
- W2045466543
- Cited by
- 141
- References
- 20
- Citations by year
- 2025: 2 · 2024: 4 · 2023: 5 · 2022: 6 · 2021: 8 · 2020: 14 · 2019: 13 · 2018: 11 · 2017: 11 · 2016: 7 · 2015: 10 · 2014: 12 · 2013: 8 · 2012: 7
- FWCI
- 8.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Endocrine Journal (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Epidemiology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Renal cell carcinoma treatment
- Keywords
- adrenocortical carcinoma, cell proliferation markers, tumor recurrence, mitotic activity, disease-free survival, overall survival, prognostic factors, adrenalectomy
- MeSH terms
- Adolescent, Adrenal Cortex Neoplasms, Adult, Aged, Female, Follow-Up Studies, Humans, Immunohistochemistry, Male, Middle Aged, Prognosis, Recurrence, Retrospective Studies, Biomarkers, Tumor, Adrenocortical Carcinoma, Ki-67 Antigen, Ubiquitin-Protein Ligases, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
